About
Darling Therapeutics is a late preclinical-stage, fully remote pharmaceutical company currently focused on addressing metabolic rare diseases via gene and cell therapies.  After authorizations of the first parts of the pipeline, i.e. at the start of P4, Darling will explore relevant next steps.
While the original vision was to build something that lasts, the market is already oversaturated with CMDOs, CROs, etc.  Founded by a female entrepreneur, Darling Therapeutics is set to be a fully remote company until 2025 expected to be sized with a small but effective management team and substantial outsourcing.  
Darling Therapeutics has an IRS EIN (88-2546870) and is a registered company trading under Darling Therapeutics Ltd. in Oxford, England and is a registered company trading under Darling Therapeutics LLC in San Francisco, California.
Back to Top